Gilead Sciences

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Simplify's Rating
Why Gilead Sciences is rated
B+
Rated B on Competitive Edge
Rated A on Growth Potential
Rated B on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Overview

Company Historically Provides H1B Sponsorship

Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and manufacturing practices. The company's goal is to enhance health equity and access to care, working with communities globally to ensure that its medicines reach those in need.

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery accelerates Gilead's R&D capabilities and innovation.
  • Manufacturing efficiencies position Gilead as a leader in CAR-T cell therapy production.
  • Long-lasting HIV prevention drugs like lenacapavir transform patient care with less frequent dosing.

What critics are saying

  • AI-driven competitors may impact Gilead's market share and innovation lead.
  • STAT6 program partnership with LEO Pharma may face clinical outcome challenges.
  • Regulatory hurdles could affect lenacapavir's market potential in HIV prevention.

What makes Gilead Sciences unique

  • Gilead's focus on HIV/AIDS and liver diseases sets it apart in biopharma.
  • Strategic partnerships enhance Gilead's research portfolio, notably in inflammation and oncology.
  • Commitment to health equity and access to care strengthens Gilead's global presence.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$4410M

Above

Industry Average

Funded Over

3 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Company News

Labiotech
Mar 27th, 2025
12 Ai Drug Discovery Companies You Should Know About

Newsletter Signup - Under Article / In Page"*" indicates required fields Artificial intelligence (AI) has taken the biotech industry by storm, allowing companies to speed up the drug discovery process while also making it more cost-effective. With so many companies in the industry now embracing the technology, we take a look at 12 AI drug discovery companies. The COVID-19 pandemic revealed AI to be an essential tool in helping to find treatments and vaccines with greater speed and precision. Since then, there have been several drug discovery breakthroughs for AI within the biopharma industry, from helping to quickly and efficiently discover a new antibiotic called abaucin to combat a multi-drug resistant bacteria, to fully discovering and designing a drug that has entered clinical trials. Here are 12 AI drug discovery companies currently making great strides with their technology. Anima Biotech Technology: mRNA biology modulators Disease areas: Immunology, oncology and neuroscienceRecent news: Announced promising preclinical data for lead pulmonary fibrosis candidate Anima Biotech’s AI drug discovery technology is built around its mRNA Lightning.AI platform, which images hundreds of cellular pathways in both healthy and diseased cells to train disease-specific AI models, making use of neural networks to help these models distinguish between healthy and diseased cells and identify dysregulated pathways. These pathways are subsequently analyzed to uncover novel targets backed by experimental validation. Anima currently has 20 preclinical candidates being evaluated for immunology, oncology, and neuroscience indications, with its most advanced candidate indicated for the treatment of lung fibrosis. The company announced in February 2024 that this candidate had shown promising preclinical results and could open up new avenues for treating patients with idiopathic pulmonary fibrosis. The AI drug discovery company also has ongoing collaborations with several pharma giants. After initially partnering with Eli Lilly in 2018 and Takeda in 2021, its most recent partnership was formed with AbbVie in 2023 for the discovery and development of mRNA biology modulators against oncology and immunology targets. Atomwise Technology: TYK2 inhibitor  Disease area: Autoimmune and autoinflammatory diseasesRecent news: Published results showcasing AtomNet’s ability for drug discoveryAtomwise is leveraging the power of AI in an attempt to revolutionize small molecule drug discovery

Charities.org
Mar 25th, 2025
Sustainability News provided by 3BL

Gilead recently partnered with GRYT Health to host a New Lens on Lung Cancer workshop where people living with lung cancer and their loved ones shared their experience with stigma.

CSR Company
Mar 18th, 2025
Gilead Sciences Ranked in Top Five Most JUST List for Biopharma Companies

Gilead Sciences ranked in top five Most JUST list for biopharma companies.

Pipeline Review
Mar 12th, 2025
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

First clinical data for Gilead's investigational Once-Yearly Lenacapavir for HIV Prevention presented at CROI 2025 and published in The Lancet.

Medical Xpress
Mar 12th, 2025
Reformulation of HIV prevention drug lenacapavir makes it last for a year

Last year, a team at Gilead announced that they had developed a PrEP called lenacapavir that could provide complete protection against HIV infections with injections every six months.

There are no jobs for Gilead Sciences right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →